LEXEO THERAPEUTICS Share Price Today: Live Updates & Key Insights
LEXEO THERAPEUTICS share price today is $5.65, up -2.42%. The stock opened at $5.815 against the previous close of $5.79, with an intraday high of $5.815 and low of $5.55.
LEXEO THERAPEUTICS Share Price Chart
LEXEO THERAPEUTICS
LEXEO THERAPEUTICS Share Price Performance
LEXEO THERAPEUTICS Institutional Holdings
LEXEO THERAPEUTICS Market Status
LEXEO THERAPEUTICS Fundamentals
Market Cap 412.38 M
PB Ratio 3.4853
PE Ratio 0.0
Enterprise Value 298.80 M
Total Assets 146.94 M
Volume 1982525
LEXEO THERAPEUTICS Company Financials
About LEXEO THERAPEUTICS & investment objective
Company Information Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Organisation Biotechnology
Employees 61
Industry Biotechnology
CEO Mr. R. Nolan Townsend M.B.A.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
LEXEO THERAPEUTICS FAQs
What is the share price of LEXEO THERAPEUTICS today?
The current share price of LEXEO THERAPEUTICS is $5.65.
Can I buy LEXEO THERAPEUTICS shares in India?
Yes, Indian investors can buy LEXEO THERAPEUTICS shares by opening an international trading and demat account with Motilal Oswal.
How to buy LEXEO THERAPEUTICS shares in India?
You can easily invest in LEXEO THERAPEUTICS shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy LEXEO THERAPEUTICS shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of LEXEO THERAPEUTICS.
Can I buy fractional shares of LEXEO THERAPEUTICS?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of LEXEO THERAPEUTICS?
LEXEO THERAPEUTICS has a market cap of $412.38 M.
In which sector does LEXEO THERAPEUTICS belong?
LEXEO THERAPEUTICS operates in the Biotechnology sector.
What documents are required to invest in LEXEO THERAPEUTICS stocks?
To invest, you typically need:
What is the PE and PB ratio of LEXEO THERAPEUTICS?
The PE ratio of LEXEO THERAPEUTICS is N/A and the PB ratio is 3.49.